IQVIA (IQV) 10-Q 31 Jul 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 24, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'Q	'
Entity Registrant Name	'Quintiles Transnational Holdings Inc.	'
Entity Central Index Key	'0001478242	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	127,276,903

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Service revenues	$1,035,476	$944,238	$2,040,764	$1,871,673
Reimbursed expenses	305,554	351,442	608,112	652,848
Total revenues	1,341,030	1,295,680	2,648,876	2,524,521
Costs, expenses and other:	'	'	'	'
Costs of revenue, service costs	674,514	617,666	1,318,236	1,228,775
Costs of revenue, reimbursed expenses	305,554	351,442	608,112	652,848
Selling, general and administrative	219,014	228,838	438,256	428,140
Restructuring costs	948	2,837	1,956	4,696
Income from operations	141,000	94,897	282,316	210,062
Interest income	-994	-785	-2,249	-1,237
Interest expense	24,799	31,884	49,502	67,926
Loss on extinguishment of debt	'	16,543	'	16,543
Other expense (income), net	3,056	536	-1,788	-1,846
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates	114,139	46,719	236,851	128,676
Income tax expense	32,400	8,830	69,789	40,948
Income before equity in earnings (losses) of unconsolidated affiliates	81,739	37,889	167,062	87,728
Equity in earnings (losses) of unconsolidated affiliates	3,371	464	8,262	-1,219
Net income	85,110	38,353	175,324	86,509
Net loss (income) attributable to noncontrolling interests	10	164	-21	317
Net income attributable to Quintiles Transnational Holdings Inc.	$85,120	$38,517	$175,303	$86,826
Earnings per share attributable to common shareholders:	'	'	'	'
Basic	$0.66	$0.31	$1.35	$0.73
Diluted	$0.64	$0.30	$1.32	$0.71
Weighted average common shares outstanding:	'	'	'	'
Basic	128,979	122,709	129,439	119,239
Diluted	132,042	126,578	132,541	122,659

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
Net income	$85,110	$38,353	$175,324	$86,509
Unrealized (losses) gains on marketable securities, net of income taxes of ($1,498), $0, ($290) and $26	-2,393	'	-463	42
Unrealized gains (losses) on derivative instruments, net of income taxes of $17, $223, ($108) and ($974)	928	496	1,250	-2,700
Foreign currency translation, net of income taxes of $0, $4,305, $0 and ($330)	3,861	-12,716	4,164	-28,354
Reclassification adjustments:	'	'	'	'
Gains on marketable securities included in net income, net of income taxes of ($1,927)	'	'	-3,077	'
Losses on derivative instruments included in net income, net of income taxes of $736, $1,320, $1,530 and $2,688	121	2,272	496	4,818
Amortization of prior service costs and losses included in net income, net of income taxes of $72, $94, $144 and $195	121	155	241	321
Comprehensive income	87,748	28,560	177,935	60,636
Comprehensive loss (income) attributable to noncontrolling interests	9	158	-12	309
Comprehensive income attributable to Quintiles Transnational Holdings Inc.	$87,757	$28,718	$177,923	$60,945

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
Unrealized (losses) gains on marketable securities, income taxes	($1,498)	$0	($290)	$26
Unrealized gains (losses) on derivative instruments, income taxes	17	223	-108	-974
Foreign currency translation, income taxes	0	4,305	0	-330
Gains on marketable securities included in net income, income taxes	'	'	-1,927	'
Losses on derivative instruments included in net income, income taxes	736	1,320	1,530	2,688
Amortization of prior service costs and losses included in net income, income taxes	$72	$94	$144	$195

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$636,468	$778,143
Restricted cash	3,296	2,712
Trade accounts receivable and unbilled services, net	964,346	924,205
Prepaid expenses	56,837	42,801
Deferred income taxes	92,842	92,115
Income taxes receivable	16,885	16,171
Other current assets and receivables	94,033	89,541
Total current assets	1,864,707	1,945,688
Property and equipment, net	196,382	199,578
Investments in debt, equity and other securities	33,741	40,349
Investments in and advances to unconsolidated affiliates	33,682	22,927
Goodwill	410,333	409,626
Other identifiable intangibles, net	282,499	298,054
Deferred income taxes	33,687	32,864
Deposits and other assets	123,606	117,711
Total assets	2,978,637	3,066,797
Current liabilities:	'	'
Accounts payable and accrued expenses	751,649	861,805
Unearned income	516,076	538,585
Income taxes payable	32,812	35,778
Current portion of long-term debt and obligations held under capital leases	20,715	10,433
Other current liabilities	31,808	35,646
Total current liabilities	1,353,060	1,482,247
Long-term debt and obligations held under capital leases, less current portion	2,026,909	2,035,586
Deferred income taxes	33,899	37,541
Other liabilities	186,379	178,908
Total liabilities	3,600,247	3,734,282
Commitments and contingencies	'	'
Shareholders' deficit:	'	'
Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 127,117 and 129,652 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	346,085	478,144
Accumulated deficit	-969,878	-1,145,181
Accumulated other comprehensive income (loss)	2,244	-376
Deficit attributable to Quintiles Transnational Holdings Inc.'s shareholders	-621,549	-667,413
Deficit attributable to noncontrolling interests	-61	-72
Total shareholders' deficit	-621,610	-667,485
Total liabilities and shareholders' deficit	$2,978,637	$3,066,797

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$0.01	$0.01
Common stock, shares issued	127,117,000	129,652,000
Common stock, shares outstanding	127,117,000	129,652,000

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating activities:	'	'
Net income	$175,324	$86,509
Adjustments to reconcile net income to cash provided by operating activities:	'	'
Depreciation and amortization	58,933	49,626
Amortization of debt issuance costs and discount	3,191	15,258
Share-based compensation	15,601	11,091
Gain on disposals of property and equipment, net	-258	-558
(Earnings) loss from unconsolidated affiliates	-8,239	1,326
Gain on investments, net	-5,114	-5
Benefit from deferred income taxes	-1,173	-12,041
Excess income tax benefits on stock option exercises	-8,613	-409
Changes in operating assets and liabilities:	'	'
Change in accounts receivable, unbilled services and unearned income	-61,568	-127,238
Change in other operating assets and liabilities	-129,387	-22,174
Net cash provided by operating activities	38,697	1,385
Investing activities:	'	'
Acquisition of property, equipment and software	-35,832	-60,277
Acquisition of business, net of cash acquired	-667	'
Proceeds from disposition of property and equipment	537	1,032
Proceeds from sale of equity securities	5,861	60
Investments in and advances to unconsolidated affiliates, net of payments received	-2,336	-4,668
Other	-571	453
Net cash used in investing activities	-33,008	-63,400
Financing activities:	'	'
Repayment of debt and principal payments on capital lease obligations	-466	-384,825
Issuance of common stock, net of costs	'	489,941
Exercise of stock options	11,313	253
Repurchase of common stock	-165,131	'
Payroll taxes remitted on repurchase of stock options	-8,415	'
Excess income tax benefits on stock option exercises	8,613	409
Net cash (used in) provided by financing activities	-154,086	105,778
Effect of foreign currency exchange rate changes on cash	6,722	-25,769
(Decrease) increase in cash and cash equivalents	-141,675	17,994
Cash and cash equivalents at beginning of period	778,143	567,728
Cash and cash equivalents at end of period	$636,468	$585,722

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	1. Basis of Presentation
	Unaudited Interim Financial Information
	The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. The balance sheet at December 31, 2013 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP.
	Reclassifications
	Certain prior period amounts have been reclassified to conform to current period presentation. These changes had no effect on previously reported total revenues, net income, comprehensive income or shareholders’ deficit.
	Recently Issued Accounting Standards
	In May 2014, the United States Financial Accounting Standards Board and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition and changes in assets and liabilities that result from contracts with customers. The Company will adopt the new standard on January 1, 2017, as required. Early adoption is not permitted. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

Employee_Stock_Compensation

Employee Stock Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Employee Stock Compensation	'
	2. Employee Stock Compensation
	The Company granted the following share-based awards:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Stock options		335,100			2,025,500			1,359,600		2,100,500
	Stock appreciation rights		—			152,600			176,800		152,600
	Restricted stock units		36,500			—			36,500		—
	The Company had the following share-based awards outstanding:
		June 30,			December 31,
		2014			2013
	Stock options		10,416,975			10,100,160
	Stock appreciation rights		421,563			258,025
	Restricted stock units		93,667			57,167
	The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows:
		Three Months Ended June 30,			Six Months Ended June 30,
		2014		2013	2014		2013
	Expected volatility	31 – 43%		18 – 44%	31 – 43%		18 – 47%
	Weighted average expected volatility	37%		40%	37%		40%
	Expected dividends	0.00%		0.00%	0.00%		0.0 – 5.45%
	Expected term (in years)	3.7 – 6.7		0.25 – 6.4	3.7 – 6.7		0.25 – 6.4
	Risk-free interest rate	1.15 – 2.13%		0.04 – 1.8%	0.99 – 2.21%		0.04 – 1.8%
	In November 2013, the Company’s Board of Directors (the “Board”) approved an Employee Stock Purchase Plan (“ESPP”) which was approved by the Company’s shareholders in May 2014. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary to be applied toward the purchase of full shares of the Company’s common stock on the last day of the offering period. Offering periods under the ESPP are six months in duration and begin on each March 1 and September 1. The first offering period for the ESPP began March 1, 2014. Under the ESPP, shares will be purchased on the last day of each offering period at a discount of 15% of the closing price of the common stock on such date as reported on the New York Stock Exchange. As of June 30, 2014, there have been aggregate payroll contributions of approximately $1.6 million related to the ESPP.
	The Company recognized share-based compensation expense of $8.4 million and $6.6 million during the three months ended June 30, 2014 and 2013, respectively, and $15.6 million and $11.1 million during the six months ended June 30, 2014 and 2013, respectively.

Concentration_of_Credit_Risk

Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2014
Risks And Uncertainties [Abstract]	'
Concentration of Credit Risk	'
	3. Concentration of Credit Risk
	No customer accounted for 10% or more of consolidated service revenues for the three and six months ended June 30, 2014 or 2013.

Accounts_Receivable_and_Unbill

Accounts Receivable and Unbilled Services	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Accounts Receivable and Unbilled Services	'
	4. Accounts Receivable and Unbilled Services
	Accounts receivable and unbilled services consist of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Trade:
	Billed	$	440,711	$	408,959
	Unbilled services		525,682		516,942
			966,393		925,901
	Allowance for doubtful accounts		(2,047)		(1,696)
		$	964,346	$	924,205

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	5. Goodwill
	The following is a summary of goodwill by segment for the six months ended June 30, 2014 (in thousands):
		Product		Integrated		Consolidated
		Development		Healthcare
				Services
	Balance as of December 31, 2013	$	351,144	$	58,482	$	409,626
	Impact of foreign currency fluctuations and other		(314)		1,021		707
	Balance as of June 30, 2014	$	350,830	$	59,503	$	410,333

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivatives	'
	6. Derivatives
	As of June 30, 2014, the Company held the following derivative positions: (i) freestanding warrants to purchase shares of common stock of third parties, (ii) forward exchange contracts to protect against foreign exchange movements for certain forecasted foreign currency cash flows related to service contracts and (iii) interest rate swaps to hedge the exposure to variability in interest payments on variable interest rate debt. The Company does not use derivative financial instruments for speculative or trading purposes.
	As of June 30, 2014, the Company had freestanding warrants to purchase shares of third parties’ common stock. No quoted price is available for the warrants. Accordingly, the Company uses various valuation techniques to value the warrants, including the present value of estimated expected future cash flows, option-pricing models and fundamental analysis. Factors affecting the valuation include the current price of the underlying common stock, the exercise price of the warrants, the expected time to exercise the warrants, the estimated price volatility of the underlying common stock over the life of the warrants and the restrictions on the transferability of or ability to exercise the warrants. The Company did not sell any warrants during the three and six months ended June 30, 2014 or 2013.
	As of June 30, 2014, the Company had 18 open foreign exchange forward contracts to hedge certain forecasted foreign currency cash flow transactions occurring in 2014 and the first three months of 2015 with notional amounts totaling $83.1 million. As these contracts were executed to hedge the risk of the potential volatility in the cash flows resulting from fluctuations in currency exchange rates during the remainder of 2014 and the first three months of 2015, these transactions are accounted for as cash flow hedges. As such, the effective portion of the gain or loss on the contracts is recorded as unrealized gains (losses) on derivatives included in the accumulated other comprehensive income (loss) (“AOCI”) component of shareholders’ deficit. These hedges are highly effective. Upon expiration of the hedge instruments in 2014 and the first three months of 2015, the Company will reclassify the unrealized holding gains and losses on the derivative instruments included in AOCI into earnings.
	On June 9, 2011, the Company entered into six interest rate swaps effective September 28, 2012 and expiring between September 30, 2013 and March 31, 2016 in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. The critical terms of the interest rate swaps were substantially the same as those of the Company’s senior secured credit facilities, including quarterly interest settlements. These interest rate swaps are being accounted for as cash flow hedges as these transactions were executed to hedge the Company’s interest payments, and these hedges are highly effective. As such, changes in the fair value of these derivative instruments are recorded as unrealized gains (losses) on derivatives included in the AOCI component of shareholders’ deficit. The fair value of these interest rate swaps represents the present value of the anticipated net payments the Company will make to the counterparty, which, when they occur, are reflected as interest expense on the condensed consolidated statements of income. These payments, together with the variable rate of interest incurred on the underlying debt, result in a fixed rate of interest of 2.55% plus the applicable margin on the affected borrowings ($945.0 million or 45.9% of the Company’s variable rate debt at June 30, 2014). The Company expects that $12.3 million of unrealized losses will be reclassified out of AOCI and will form the interest rate swap component of the 2.55% fixed rate of interest to be incurred over the next 12 months as the underlying net payments are settled.
	The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands):
		Balance Sheet Classification		June 30,				December 31,
				2014				2013
	Foreign exchange forward contracts	Other current assets		$	2,806			$	3,950
	Interest rate swaps	Other current liabilities		$	20,493			$	24,805
	The fair values of the Company’s derivative instruments not designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands):
		Balance Sheet Classification		June 30,		December 31,
				2014		2013
	Warrants	Deposits and other assets		$              395		$              211
	The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands):
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
	Foreign exchange forward contracts	$	(335	)		$	766			$	(1,144	)	$	(1,625	)
	Interest rate swaps		2,137				3,545				4,312			5,457
	Total	$	1,802			$	4,311			$	3,168		$	3,832

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	7. Fair Value Measurements
	The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
		•		Level 1 — Quoted prices in active markets for identical assets or liabilities.
		•		Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
		•		Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
	Recurring Fair Value Measurements
	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of June 30, 2014 (in thousands):
			Level 1		Level 2		Level 3		Total
	Assets:
	Marketable equity securities		$	1,055	$	—	$	—	$	1,055
	Foreign exchange forward contracts			—		2,806		—		2,806
	Warrants			—		—		395		395
	Total		$	1,055	$	2,806	$	395	$	4,256
	Liabilities:
	Interest rate swaps		$	—	$	20,493	$	—	$	20,493
	Contingent consideration			—		—		13,200		13,200
	Total		$	—	$	20,493	$	13,200	$	33,693
	Below is a summary of the valuation techniques used in determining fair value:
	Marketable equity securities — The Company values marketable equity securities utilizing quoted market prices.
	Foreign exchange forward contracts — The Company values foreign exchange forward contracts using quoted market prices for identical instruments in less active markets or using other observable inputs.
	Warrants — The Company values warrants utilizing the Black-Scholes-Merton model.
	Interest rate swaps — The Company values interest rate swaps using market inputs with mid-market pricing as a practical expedient for bid-ask spread.
	Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue, net new business and operating forecasts and the probability of achieving the specific targets.
	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the six months ended June 30 (in thousands):
			Warrants – Deposits				Contingent Consideration –
			and Other Assets				Accounts Payable and Accrued
							Expenses and Other Liabilities
			2014		2013		2014		2013
	Balance as of January 1		$	211	$	29	$	13,014	$	3,521
	Revaluations included in earnings			184		5		186		-113
	Balance as of June 30		$	395	$	34	$	13,200	$	3,408
	The revaluations for the warrants and the contingent consideration are recognized in other expense (income), net on the accompanying condensed consolidated statements of income.
	Non-recurring Fair Value Measurements
	Certain assets are carried on the accompanying condensed consolidated balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include cost and equity method investments and loans that are written down to fair value for declines which are deemed to be other-than-temporary, and goodwill and identifiable intangible assets which are tested for impairment annually and when a triggering event occurs.
	As of June 30, 2014, assets carried on the balance sheet and not remeasured to fair value on a recurring basis totaling approximately $759.2 million were identified as Level 3. These assets are comprised of cost and equity method investments of $66.4 million, goodwill of $410.3 million and other identifiable intangibles, net of $282.5 million.
	The Company has unfunded cash commitments totaling approximately $31.9 million related to its cost and equity method investments as of June 30, 2014.
	Other
	The estimated fair value of the Company’s long-term debt, which is primarily based on rates in which the debt is traded among banks, was approximately $2.1 billion at both June 30, 2014 and December 31, 2013.

Shareholders_Deficit

Shareholders' Deficit	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Shareholders' Deficit	'
	8. Shareholders’ Deficit
	Equity Repurchase Program
	On October 30, 2013, the Board approved an equity repurchase program (the “Repurchase Program”) authorizing the repurchase of up to $125.0 million of either the Company’s common stock or vested in-the-money employee stock options, or a combination thereof. The Company repurchased 300 shares of its common stock for $47.51 per share for an aggregate purchase price of approximately $14,000 during the six months ended June 30, 2014 under the Repurchase Program. As of June 30, 2014, the Company has remaining authorization under the Repurchase Program to repurchase up to $59.5 million of its common shares. The Repurchase Program for vested in-the-money employee stock options expired in November 2013. The Repurchase Program for common stock does not have an end date.
	Private Share Repurchase
	On May 28, 2014, the Company completed the repurchase of 3,287,209 shares of its common stock for $50.23 per share from TPG Quintiles Holdco, L.P., one of its existing shareholders, in a private transaction for an aggregate purchase price of approximately $165.1 million. The repurchase price per share of common stock was equal to 98% of the closing market price of the Company’s common stock on the New York Stock Exchange on May 27, 2014 (which was $51.26). The repurchase of shares from its existing shareholder was approved in compliance with the Company’s related party transactions approval policy. The Company funded this private repurchase transaction with cash on hand. This private repurchase transaction was separate from and in addition to the Repurchase Program.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2014
Restructuring And Related Activities [Abstract]	'
Restructuring	'
	9. Restructuring
	In February 2014, the Board approved a restructuring plan of up to $13.0 million to better align resources with the Company’s strategic direction. These actions are expected to occur throughout 2014 and are expected to result in severance for approximately 400 positions, primarily in the Product Development segment. Since February 2014, the Company has recognized approximately $2.8 million of restructuring costs related to this plan, all of which were for activities in the Product Development segment. All of the restructuring costs are related to severance costs. Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management.
	The following amounts were recorded for the February 2014 restructuring plan and the restructuring plans initiated in prior years (in thousands):
		Severance and		Exit Costs		Total
		Related Costs
	Balance at December 31, 2013	$	5,276	$	198	$	5,474
	Expense, net of reversals		1,956		—		1,956
	Payments		-4,327		(77)		-4,404
	Foreign currency translation		-31		—		-31
	Balance at June 30, 2014	$	2,874	$	121	$	2,995
	The Company expects the majority of the restructuring accruals at June 30, 2014 will be paid in 2014.

Employee_Benefit_Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2014
Postemployment Benefits [Abstract]	'
Employee Benefit Plans	'
	10. Employee Benefit Plans
	Defined Benefit Plans
	The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Service cost	$	3,391	$	2,981	$	6,678	$	6,134
	Interest cost		1,003		920		1,990		1,858
	Expected return on plan assets		-942		-686		-1,870		-1,378
	Amortization of prior service costs		20		83		40		172
	Amortization of actuarial losses		173		166		345		344
		$	3,645	$	3,464	$	7,183	$	7,130
	Other
	As of June 30, 2014 and December 31, 2013, the Company has a severance accrual included in accounts payable and accrued expenses on the accompanying condensed consolidated balance sheets of $9.0 million and $14.1 million, respectively. The Company recognizes obligations associated with severance related to contractual termination benefits at fair value on the date that it is probable that the affected employees will be entitled to the benefit and the amount can reasonably be estimated. The severance accrual is related to cost reduction programs that will result in severance for approximately 270 positions, which are expected to lower operating costs and improve profitability by reducing excess capacity. These actions are expected to occur and be paid during 2014 and 2015. During the first six months of 2014, the Company has recognized approximately $2.5 million of net reversals related to these cost reduction programs, primarily as a result of affected individuals transferring into other positions within the Company. Of the $2.5 million decrease from net reversals recognized for these cost reduction programs, approximately ($2.6) million, $149,000 and ($80,000) were related to activities in the Product Development segment, Integrated Healthcare Services segment and corporate activities, respectively.
	The following amounts were recorded for the severance associated with cost reduction programs (in thousands):
	Balance at December 31, 2013	$	14,056
	Expense, net of reversals		-2,536
	Payments		-2,560
	Foreign currency translation		6
	Balance at June 30, 2014	$	8,966

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	11. Income Taxes
	The Company’s effective income tax rate was 28.4% and 18.9% for the three months ended June 30, 2014 and 2013, respectively, and 29.5% and 31.8% for the six months ended June 30, 2014 and 2013, respectively. The effective income tax rate for the three and six months ended June 30, 2013 was positively impacted by a $16.2 million discrete income tax benefit recognized as a result of the management agreement termination fee and costs associated with debt repayments. The effective income tax rate for the three and six months ended June 30, 2013 was negatively impacted by the settlement of certain intercompany notes that had previously been considered long-term investments, which resulted in $11.2 million of income tax expense.
	In addition, the effective income tax rate for the three and six months ended June 30, 2013, and for subsequent periods, was positively impacted by the Company’s change in the assertion regarding the undistributed earnings of most of its foreign subsidiaries that are considered to be indefinitely reinvested outside of the United States. Prior to June 2013, the Company had not considered the majority of the undistributed earnings of its foreign subsidiaries to be indefinitely reinvested. Accordingly, periods prior to June 2013 were negatively impacted by income taxes imposed on most of the earnings of the foreign subsidiaries, as a deferred income tax liability was recorded each quarter for the anticipated income tax costs of repatriating those earnings in the future. Management reevaluated this assertion following the Company’s initial public offering (“IPO”) in May 2013, as a portion of the IPO proceeds were used to pay down debt held in the United States. With this reduction of debt and related interest expense, the Company expects to be able to support the cash needs of the domestic subsidiaries without repatriating cash from the affected foreign subsidiaries. The Company expects to utilize the cash generated outside of the United States to fund growth outside of the United States. As a result of the assertion change, the Company recorded an $8.1 million income tax benefit in the second quarter of 2013 to reverse the deferred income tax liability previously recorded on undistributed foreign earnings prior to 2013 that are now considered indefinitely reinvested outside of the United States. In addition, the estimated annual effective income tax rate for 2013 decreased due to the indefinitely reinvested assertion, which resulted in a $7.3 million one-time income tax benefit for the three months ended June 30, 2013 to adjust income taxes recorded on the first quarter of 2013 earnings to the new estimated annual effective income tax rate.

Comprehensive_Income

Comprehensive Income	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Comprehensive Income	'
	12. Comprehensive Income
	Below is a summary of the components of AOCI (in thousands):
		Foreign				Marketable				Derivative				Defined				Income		AOCI
		Currency				Securities				Instruments				Benefit				Taxes
		Translation												Plans
	Balance at December 31, 2013	$	(5,829)			$	5,708			$	(20,855)			$	(5,044)			$	25,644	$	(376)
	Other comprehensive income (loss) before reclassifications		4,173				(753)				1,142				—				398		4,960
	Reclassification adjustments		—				(5,004)				2,026				385				253		(2,340)
	Balance at June 30, 2014	$	(1,656)			$	(49)			$	(17,687)			$	(4,659)			$	26,295	$	2,244
	Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands):
	Reclassification Adjustments	Affected Financial Statement		Three Months Ended June 30,								Six Months Ended June 30,
		Line Item
				2014				2013				2014				2013
	Marketable securities:
	Marketable securities	Other expense (income), net		$	—			$	—			$	(5,004)			$	—
	Total before income taxes				—				—				(5,004)				—
	Income tax expense				—				—				(1,927)				—
	Total net of income taxes			$	—			$	—			$	(3,077)			$	—
	Derivative instruments:
	Interest rate swaps	Interest expense		$	3,115			$	3,179			$	6,195			$	6,185
	Foreign exchange forward contracts	Service revenues			(2,258)				413				(4,169)				1,321
	Total before income taxes				857				3,592				2,026				7,506
	Income tax benefit				736				1,320				1,530				2,688
	Total net of income taxes			$	121			$	2,272			$	496			$	4,818
	Defined benefit plans:
	Amortization of prior service costs	See Note 10		$	20			$	83			$	40			$	172
	Amortization of actuarial losses	See Note 10			173				166				345				344
	Total before income taxes				193				249				385				516
	Income tax benefit				72				94				144				195
	Total net of income taxes			$	121			$	155			$	241			$	321

Segments

Segments	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segments	'
	13. Segments
	The following table presents the Company’s operations by reportable segment. The Company is managed through two reportable segments, Product Development and Integrated Healthcare Services. Product Development, which primarily serves biopharmaceutical customers engaged in research and development, provides clinical research and clinical trial services. Integrated Healthcare Services provides commercialization services to biopharmaceutical customers and research, analytics, real-world and late phase research, and other services to both biopharmaceutical customers and the broader healthcare market.
	Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of share-based compensation and expenses for corporate overhead functions such as finance, human resources, information technology, facilities and legal, as well as certain expenses incurred during the second quarter of 2013, including the $25.0 million fee incurred in connection with the termination of the management agreement with affiliates of certain shareholders and the $1.5 million fee paid in connection with the modification of an agreement for the business usage of an airplane owned by GF Management Company, LLC, a company owned by the Company’s Executive Chairman. The Company does not allocate restructuring or impairment charges to its segments. Information presented below is in thousands:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Service revenues
	Product Development	$	781,187	$	724,170	$	1,552,015	$	1,430,477
	Integrated Healthcare Services		254,289		220,068		488,749		441,196
	Total service revenues		1,035,476		944,238		2,040,764		1,871,673
	Costs of revenue, service costs
	Product Development		465,278		441,895		915,761		870,902
	Integrated Healthcare Services		209,236		175,771		402,475		357,873
	Total costs of revenue, service costs		674,514		617,666		1,318,236		1,228,775
	Selling, general and administrative
	Product Development		157,552		146,182		317,237		290,807
	Integrated Healthcare Services		33,346		31,790		65,622		64,571
	General corporate and unallocated		28,116		50,866		55,397		72,762
	Total selling, general and administrative		219,014		228,838		438,256		428,140
	Income from operations
	Product Development		158,357		136,093		319,017		268,768
	Integrated Healthcare Services		11,707		12,507		20,652		18,752
	General corporate and unallocated		(28,116)		(50,866)		(55,397)		(72,762)
	Restructuring costs		(948)		(2,837)		(1,956)		(4,696)
	Total income from operations	$	141,000	$	94,897	$	282,316	$	210,062
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Depreciation and amortization expense
	Product Development	$	23,791	$	18,601	$	46,761	$	37,048
	Integrated Healthcare Services		4,854		5,267		9,745		10,620
	General corporate and unallocated		1,200		1,118		2,427		1,958
	Total depreciation and amortization expense	$	29,845	$	24,986	$	58,933	$	49,626

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	14. Earnings Per Share
	The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Weighted average shares subject to anti-dilutive share-based awards		1,598		1,217		1,182		1,424
	Share-based awards will have a dilutive effect under the treasury method only when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.

Subsequent_Event

Subsequent Event	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	15. Subsequent Event
	On July 1, 2014, the Company completed the acquisition of Encore Health Resources, LLC (“Encore”) effected through a merger for approximately $93.6 million in cash. The preliminary fair value of Encore’s net assets acquired is not available as of the filing date of this Form 10-Q. Encore has operations in the United States and its business is primarily focused on providing electronic health records (“EHR”) implementation and advisory services to healthcare providers. As part of its Integrated Healthcare Services segment, the Company expects that Encore will enhance its EHR expertise.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Unaudited Interim Financial Information	'
	Unaudited Interim Financial Information
	The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. The balance sheet at December 31, 2013 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP.
Reclassifications	'
	Reclassifications
	Certain prior period amounts have been reclassified to conform to current period presentation. These changes had no effect on previously reported total revenues, net income, comprehensive income or shareholders’ deficit.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards
	In May 2014, the United States Financial Accounting Standards Board and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition and changes in assets and liabilities that result from contracts with customers. The Company will adopt the new standard on January 1, 2017, as required. Early adoption is not permitted. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

Employee_Stock_Compensation_Ta

Employee Stock Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Share Based Awards Granted and Outstanding	'
	The Company granted the following share-based awards:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Stock options		335,100			2,025,500			1,359,600		2,100,500
	Stock appreciation rights		—			152,600			176,800		152,600
	Restricted stock units		36,500			—			36,500		—
	The Company had the following share-based awards outstanding:
		June 30,			December 31,
		2014			2013
	Stock options		10,416,975			10,100,160
	Stock appreciation rights		421,563			258,025
	Restricted stock units		93,667			57,167
Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued	'
	The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows:
		Three Months Ended June 30,			Six Months Ended June 30,
		2014		2013	2014		2013
	Expected volatility	31 – 43%		18 – 44%	31 – 43%		18 – 47%
	Weighted average expected volatility	37%		40%	37%		40%
	Expected dividends	0.00%		0.00%	0.00%		0.0 – 5.45%
	Expected term (in years)	3.7 – 6.7		0.25 – 6.4	3.7 – 6.7		0.25 – 6.4
	Risk-free interest rate	1.15 – 2.13%		0.04 – 1.8%	0.99 – 2.21%		0.04 – 1.8%

Accounts_Receivable_and_Unbill1

Accounts Receivable and Unbilled Services (Tables)	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Accounts Receivable and Unbilled Services	'
	Accounts receivable and unbilled services consist of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Trade:
	Billed	$	440,711	$	408,959
	Unbilled services		525,682		516,942
			966,393		925,901
	Allowance for doubtful accounts		(2,047)		(1,696)
		$	964,346	$	924,205

Goodwill_Tables

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Summary of Goodwill by Segment	'
	The following is a summary of goodwill by segment for the six months ended June 30, 2014 (in thousands):
		Product		Integrated		Consolidated
		Development		Healthcare
				Services
	Balance as of December 31, 2013	$	351,144	$	58,482	$	409,626
	Impact of foreign currency fluctuations and other		(314)		1,021		707
	Balance as of June 30, 2014	$	350,830	$	59,503	$	410,333

Derivatives_Tables

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Fair Values of Derivative Instruments Designated as Hedges	'
	The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands):
		Balance Sheet Classification		June 30,				December 31,
				2014				2013
	Foreign exchange forward contracts	Other current assets		$	2,806			$	3,950
	Interest rate swaps	Other current liabilities		$	20,493			$	24,805
Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss)	'
	The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands):
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
	Foreign exchange forward contracts	$	(335	)		$	766			$	(1,144	)	$	(1,625	)
	Interest rate swaps		2,137				3,545				4,312			5,457
	Total	$	1,802			$	4,311			$	3,168		$	3,832
Deposits and other assets [Member]	'
Summary of Details Relating to Fair Value / Losses (Gains) of Derivative Instruments not Designated as Hedges	'
	The fair values of the Company’s derivative instruments not designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands):
		Balance Sheet Classification		June 30,		December 31,
				2014		2013
	Warrants	Deposits and other assets		$              395		$              211

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	'
	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of June 30, 2014 (in thousands):
		Level 1		Level 2		Level 3		Total
	Assets:
	Marketable equity securities	$	1,055	$	—	$	—	$	1,055
	Foreign exchange forward contracts		—		2,806		—		2,806
	Warrants		—		—		395		395
	Total	$	1,055	$	2,806	$	395	$	4,256
	Liabilities:
	Interest rate swaps	$	—	$	20,493	$	—	$	20,493
	Contingent consideration		—		—		13,200		13,200
	Total	$	—	$	20,493	$	13,200	$	33,693
Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	'
	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the six months ended June 30 (in thousands):
		Warrants – Deposits				Contingent Consideration –
		and Other Assets				Accounts Payable and Accrued
						Expenses and Other Liabilities
		2014		2013		2014		2013
	Balance as of January 1	$	211	$	29	$	13,014	$	3,521
	Revaluations included in earnings		184		5		186		(113)
	Balance as of June 30	$	395	$	34	$	13,200	$	3,408

Restructuring_Tables

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2014
Restructuring And Related Activities [Abstract]	'
Summary of Amounts Recorded for Restructuring Plans	'
	The following amounts were recorded for the February 2014 restructuring plan and the restructuring plans initiated in prior years (in thousands):
		Severance and		Exit Costs		Total
		Related Costs
	Balance at December 31, 2013	$	5,276	$	198	$	5,474
	Expense, net of reversals		1,956		—		1,956
	Payments		-4,327		(77)		-4,404
	Foreign currency translation		-31		—		-31
	Balance at June 30, 2014	$	2,874	$	121	$	2,995
	The Company expects the majority of the restructuring accruals at June 30, 2014 will be paid in 2014.

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2014
Postemployment Benefits [Abstract]	'
Summary of Components of Pension Expenses Related to Defined Benefit Plans	'
	The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Service cost	$	3,391	$	2,981	$	6,678	$	6,134
	Interest cost		1,003		920		1,990		1,858
	Expected return on plan assets		(942)		(686)		(1,870)		(1,378)
	Amortization of prior service costs		20		83		40		172
	Amortization of actuarial losses		173		166		345		344
		$	3,645	$	3,464	$	7,183	$	7,130
Summary of Severance Associated with Cost Reduction Programs	'
	The following amounts were recorded for the severance associated with cost reduction programs (in thousands):
	Balance at December 31, 2013	$	14,056
	Expense, net of reversals		-2,536
	Payments		-2,560
	Foreign currency translation		6
	Balance at June 30, 2014	$	8,966

Comprehensive_Income_Tables

Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Summary of Components of AOCI	'
	Below is a summary of the components of AOCI (in thousands):
		Foreign				Marketable				Derivative				Defined				Income		AOCI
		Currency				Securities				Instruments				Benefit				Taxes
		Translation												Plans
	Balance at December 31, 2013	$	(5,829)			$	5,708			$	(20,855)			$	(5,044)			$	25,644	$	(376)
	Other comprehensive income (loss) before reclassifications		4,173				(753)				1,142				—				398		4,960
	Reclassification adjustments		—				(5,004)				2,026				385				253		(2,340)
	Balance at June 30, 2014	$	(1,656)			$	(49)			$	(17,687)			$	(4,659)			$	26,295	$	2,244
Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	'
	Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands):
	Reclassification Adjustments	Affected Financial Statement		Three Months Ended								Six Months Ended
		Line Item		June 30,								June 30,
				2014				2013				2014				2013
	Marketable securities:
	Marketable securities	Other expense (income), net		$	—			$	—			$	(5,004)			$	—
	Total before income taxes				—				—				(5,004)				—
	Income tax expense				—				—				(1,927)				—
	Total net of income taxes			$	—			$	—			$	(3,077)			$	—
	Derivative instruments:
	Interest rate swaps	Interest expense		$	3,115			$	3,179			$	6,195			$	6,185
	Foreign exchange forward contracts	Service revenues			(2,258)				413				(4,169)				1,321
	Total before income taxes				857				3,592				2,026				7,506
	Income tax benefit				736				1,320				1,530				2,688
	Total net of income taxes			$	121			$	2,272			$	496			$	4,818
	Defined benefit plans:
	Amortization of prior service costs	See Note 10		$	20			$	83			$	40			$	172
	Amortization of actuarial losses	See Note 10			173				166				345				344
	Total before income taxes				193				249				385				516
	Income tax benefit				72				94				144				195
	Total net of income taxes			$	121			$	155			$	241			$	321

Segments_Tables

Segments (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Operations by Reportable Segments	'
	The Company does not allocate restructuring or impairment charges to its segments. Information presented below is in thousands:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Service revenues
	Product Development	$	781,187	$	724,170	$	1,552,015	$	1,430,477
	Integrated Healthcare Services		254,289		220,068		488,749		441,196
	Total service revenues		1,035,476		944,238		2,040,764		1,871,673
	Costs of revenue, service costs
	Product Development		465,278		441,895		915,761		870,902
	Integrated Healthcare Services		209,236		175,771		402,475		357,873
	Total costs of revenue, service costs		674,514		617,666		1,318,236		1,228,775
	Selling, general and administrative
	Product Development		157,552		146,182		317,237		290,807
	Integrated Healthcare Services		33,346		31,790		65,622		64,571
	General corporate and unallocated		28,116		50,866		55,397		72,762
	Total selling, general and administrative		219,014		228,838		438,256		428,140
	Income from operations
	Product Development		158,357		136,093		319,017		268,768
	Integrated Healthcare Services		11,707		12,507		20,652		18,752
	General corporate and unallocated		(28,116)		(50,866)		(55,397)		(72,762)
	Restructuring costs		(948)		(2,837)		(1,956)		(4,696)
	Total income from operations	$	141,000	$	94,897	$	282,316	$	210,062
Depreciation and Amortization Expense	'
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Depreciation and amortization expense
	Product Development	$	23,791	$	18,601	$	46,761	$	37,048
	Integrated Healthcare Services		4,854		5,267		9,745		10,620
	General corporate and unallocated		1,200		1,118		2,427		1,958
	Total depreciation and amortization expense	$	29,845	$	24,986	$	58,933	$	49,626

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Summary of Weighted-Average Outstanding Share-Based Awards Excluded from Computation of Diluted Earnings Per Share	'
	The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Weighted average shares subject to anti-dilutive share-based awards		1,598		1,217		1,182		1,424

Employee_Stock_Compensation_Sc

Employee Stock Compensation - Schedule of Share Based Awards Granted and Outstanding (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'	'	'
Stock options granted	335,100	2,025,500	1,359,600	2,100,500	'
Stock appreciation rights granted	'	152,600	176,800	152,600	'
Restricted stock units granted	36,500	'	36,500	'	'
Stock options outstanding	10,416,975	'	10,416,975	'	10,100,160
Stock appreciation rights outstanding	421,563	'	421,563	'	258,025
Restricted stock units outstanding	93,667	'	93,667	'	57,167

Employee_Stock_Compensation_As

Employee Stock Compensation - Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'	'	'	'
Expected volatility, Minimum	31.00%	18.00%	31.00%	18.00%
Expected volatility, Maximum	43.00%	44.00%	43.00%	47.00%
Weighted average expected volatility	37.00%	40.00%	37.00%	40.00%
Expected dividends	0.00%	0.00%	0.00%	'
Risk-free interest rate, Minimum	1.15%	0.04%	0.99%	0.04%
Risk-free interest rate, Maximum	2.13%	1.80%	2.21%	1.80%
Minimum [Member]	'	'	'	'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'	'	'	'
Expected dividends	'	'	'	0.00%
Expected term (in years)	'3 years 8 months 12 days	'3 months	'3 years 8 months 12 days	'3 months
Maximum [Member]	'	'	'	'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'	'	'	'
Expected dividends	'	'	'	5.45%
Expected term (in years)	'6 years 8 months 12 days	'6 years 4 months 24 days	'6 years 8 months 12 days	'6 years 4 months 24 days

Employee_Stock_Compensation_Ad

Employee Stock Compensation - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share based compensation expense	$8,400,000	$6,600,000	$15,601,000	$11,091,000
Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Employee stock purchase plan payroll deductions percent	10.00%	'	10.00%	'
Discount on closing price of share	'	'	15.00%	'
Aggregate payroll contributions	$1,600,000	'	$1,600,000	'

Concentration_of_Credit_Risk_A

Concentration of Credit Risk - Additional Information (Detail) (Sales [Member])	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
	Customer	Customer	Customer	Customer
Sales [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Number of customers served	0	0	0	0
Percentage of service revenue from major customers	10.00%	10.00%	10.00%	10.00%

Accounts_Receivable_and_Unbill2

Accounts Receivable and Unbilled Services - Accounts Receivable and Unbilled Services (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Trade:	'	'
Billed	$440,711	$408,959
Unbilled services	525,682	516,942
Trade accounts receivable and unbilled services, gross	966,393	925,901
Allowance for doubtful accounts	-2,047	-1,696
Trade accounts receivable and unbilled services, net	$964,346	$924,205

Goodwill_Summary_of_Goodwill_b

Goodwill - Summary of Goodwill by Segment (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Goodwill [Line Items]	'
Beginning balance	$409,626
Impact of foreign currency fluctuations and other	707
Ending balance	410,333
Product Development [Member]	'
Goodwill [Line Items]	'
Beginning balance	351,144
Impact of foreign currency fluctuations and other	-314
Ending balance	350,830
Integrated Healthcare Services [Member]	'
Goodwill [Line Items]	'
Beginning balance	58,482
Impact of foreign currency fluctuations and other	1,021
Ending balance	$59,503

Derivatives_Additional_Informa

Derivatives - Additional Information (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 09, 2011	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
In Millions, unless otherwise specified		Minimum [Member]	Maximum [Member]	Foreign Exchange Forward Contracts [Member]	Interest Rate Swaps [Member]	Interest Rate Swaps [Member]	Warrants [Member]	Warrants [Member]	Warrants [Member]	Warrants [Member]
				Derivative		Agreement	Warrants	Warrants	Warrants	Warrants
Derivatives And Hedging Activities [Line Items]	'	'	'	'	'	'	'	'	'	'
Warrant Sold	'	'	'	'	'	'	0	0	0	0
Number of foreign exchange forward contracts	'	'	'	18	'	6	'	'	'	'
Notional amount	'	'	'	$83.10	'	'	'	'	'	'
Expiration year of hedge instruments	'	'	'	'2014	'	'	'	'	'	'
Interest rate swaps expiry date	'	30-Sep-13	31-Mar-16	'	'	'	'	'	'	'
Interest Rate Cash Flow Hedge Loss to be Reclassified During Next 12 Months, Net	12.3	'	'	'	'	'	'	'	'	'
Derivative fixed interest rate	2.55%	'	'	'	'	'	'	'	'	'
Interest rate swaps hedged amount due to future change in interest rate swaps	'	'	'	'	$945	'	'	'	'	'
Interest rate swaps effectively converted percent	45.90%	'	'	'	'	'	'	'	'	'

Derivatives_Summary_of_Fair_Va

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) (Designated as Hedging Instrument [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Foreign Exchange Forward Contracts [Member] | Other Current Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset fair value	$2,806	$3,950
Interest Rate Swaps [Member] | Other Current Liabilities [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability fair value	$20,493	$24,805

Derivatives_Summary_of_Details

Derivatives - Summary of Details Relating to Fair Value / Losses (Gains) of Derivative Instruments not Designated as Hedges (Detail) (Warrants [Member], Derivatives Not Designated as Hedging Instruments [Member], Deposits and other assets [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Warrants [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Deposits and other assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset fair value	$395	$211

Derivatives_Effect_of_Cash_Flo

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss) (Detail) (Derivatives Designated As Cash Flow Hedges [Member], USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Derivative Instruments and Hedging Activities Disclosures [Line Items]	'	'	'	'
Effect of cash flow hedging instruments on other comprehensive income (loss)	$1,802	$4,311	$3,168	$3,832
Foreign Exchange Forward Contracts [Member]	'	'	'	'
Derivative Instruments and Hedging Activities Disclosures [Line Items]	'	'	'	'
Effect of cash flow hedging instruments on other comprehensive income (loss)	-335	766	-1,144	-1,625
Interest Rate Swaps [Member]	'	'	'	'
Derivative Instruments and Hedging Activities Disclosures [Line Items]	'	'	'	'
Effect of cash flow hedging instruments on other comprehensive income (loss)	$2,137	$3,545	$4,312	$5,457

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) (Recurring Fair Value Measurements [Member], USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	$4,256
Fair value of liabilities	33,693
Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	395
Foreign Exchange Forward Contracts [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	2,806
Interest Rate Swaps [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of liabilities	20,493
Contingent Consideration [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of liabilities	13,200
Marketable Equity Securities [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	1,055
Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	1,055
Fair value of liabilities	'
Level 1 [Member] | Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	'
Level 1 [Member] | Foreign Exchange Forward Contracts [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	'
Level 1 [Member] | Interest Rate Swaps [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of liabilities	'
Level 1 [Member] | Contingent Consideration [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of liabilities	'
Level 1 [Member] | Marketable Equity Securities [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	1,055
Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	2,806
Fair value of liabilities	20,493
Level 2 [Member] | Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	'
Level 2 [Member] | Foreign Exchange Forward Contracts [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	2,806
Level 2 [Member] | Interest Rate Swaps [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of liabilities	20,493
Level 2 [Member] | Contingent Consideration [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of liabilities	'
Level 2 [Member] | Marketable Equity Securities [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	'
Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	395
Fair value of liabilities	13,200
Level 3 [Member] | Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	395
Level 3 [Member] | Foreign Exchange Forward Contracts [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	'
Level 3 [Member] | Interest Rate Swaps [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of liabilities	'
Level 3 [Member] | Contingent Consideration [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of liabilities	13,200
Level 3 [Member] | Marketable Equity Securities [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Fair value of assets	'

Fair_Value_Measurements_Change

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) (Level 3 [Member], USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Accounts Payable and Accrued Expenses and Other Liabilities [Member] | Contingent Consideration [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance, contingent Consideration	$13,014	$3,521
Revaluations included in earnings	186	-113
Ending Balance, contingent Consideration	13,200	3,408
Deposits and Other Assets [Member] | Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance, Warrants	211	29
Revaluations included in earnings	184	5
Ending Balance, Warrants	$395	$34

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other identifiable intangibles, net	$282,499,000	$298,054,000
Long term debt	2,100,000,000	2,100,000,000
Non-recurring Fair Value Measurements [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cost and equity method investments	66,400,000	'
Goodwill	410,300,000	'
Other identifiable intangibles, net	282,499,000	'
Fair value of assets	759,200,000	'
Non-recurring Fair Value Measurements [Member] | Level 3 [Member] | Equity Method Investments [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Unfunded cash commitments	$31,900,000	'

Shareholders_Deficit_Additiona

Shareholders' Deficit - Additional Information (Detail) (USD $)	0 Months Ended			6 Months Ended
	28-May-14	27-May-14	Oct. 30, 2013	Jun. 30, 2014
	Private Share Repurchase [Member]	Private Share Repurchase [Member]	Equity Repurchase Program [Member]	Equity Repurchase Program [Member]
Class of Stock [Line Items]	'	'	'	'
Repurchase of common stock, shares	3,287,209	'	300	'
Repurchase of common stock, value	$165,100,000	'	$14,000	'
Repurchase of common stock, share price	$50.23	$51.26	$47.51	'
Equity available for repurchase under the repurchase program	'	'	'	59,500,000
Equity repurchase program authorized amount	'	'	$125,000,000	'
Repurchase price per share percentage	'	98.00%	'	'

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended	5 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Feb. 28, 2014	Jun. 30, 2014
					2014 Restructuring Plan [Member]	2014 Restructuring Plan [Member]
					Position	Product Development [Member]
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring plan approved	'	'	'	'	$13,000,000	'
Number of positions expected to reduce	'	'	'	'	400	'
Restructuring costs	$948,000	$2,837,000	$1,956,000	$4,696,000	'	$2,800,000

Restructuring_Summary_of_Amoun

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Restructuring Cost and Reserve [Line Items]	'
Restructuring reserves, beginning balance	$5,474
Expense, net of reversals	1,956
Payments	-4,404
Foreign currency translation	-31
Restructuring reserves, ending balance	2,995
Severance and Related Costs [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Restructuring reserves, beginning balance	5,276
Expense, net of reversals	1,956
Payments	-4,327
Foreign currency translation	-31
Restructuring reserves, ending balance	2,874
Exit Costs [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Restructuring reserves, beginning balance	198
Expense, net of reversals	0
Payments	-77
Foreign currency translation	0
Restructuring reserves, ending balance	$121

Employee_Benefit_Plans_Summary

Employee Benefit Plans - Summary of Components of Pension Expenses Related to Defined Benefit Plans (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Compensation And Retirement Disclosure [Abstract]	'	'	'	'
Service cost	$3,391	$2,981	$6,678	$6,134
Interest cost	1,003	920	1,990	1,858
Expected return on plan assets	-942	-686	-1,870	-1,378
Amortization of prior service costs	20	83	40	172
Amortization of actuarial losses	173	166	345	344
Total pension expense related to defined benefit plans	$3,645	$3,464	$7,183	$7,130

Employee_Benefit_Plans_Additio

Employee Benefit Plans - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Cost Reduction Initiative Disclosure [Line Items]	'	'
Severance expenses payable	$8,966,000	$14,056,000
Severance expense, net of reversals	2,536,000	'
Corporate, Non-Segment [Member]	'	'
Cost Reduction Initiative Disclosure [Line Items]	'	'
Severance expense, net of reversals	80,000	'
Product Development [Member]	'	'
Cost Reduction Initiative Disclosure [Line Items]	'	'
Severance expense, net of reversals	2,536,000	'
Integrated Healthcare Services [Member]	'	'
Cost Reduction Initiative Disclosure [Line Items]	'	'
Severance expense, net of reversals	149,000	'
Cost Reduction Initiative [Member]	'	'
Cost Reduction Initiative Disclosure [Line Items]	'	'
Severance expenses payable	$8,966,000	$14,056,000
Number of positions expected to be eliminated	270	'

Employee_Benefit_Plans_Summary1

Employee Benefit Plans - Summary of Severance Associated with Cost Reduction Programs (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Compensation And Retirement Disclosure [Abstract]	'
Severance expenses payable, opening balance	$14,056
Severance expense, net of reversals	-2,536
Severance payments	-2,560
Severance foreign currency translation	6
Severance expenses payable, ending balance	$8,966

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Effective income tax rate	28.40%	18.90%	29.50%	31.80%
Discrete income tax benefit	'	$16.20	'	$16.20
Discrete income tax expense	'	11.2	'	11.2
Income tax benefit to reverse the deferred income tax liability on undistributed foreign earnings	8.1	'	'	'
One time income tax benefit	$7.30	'	'	'

Comprehensive_Income_Summary_o

Comprehensive Income - Summary of Components of AOCI (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning Balance	($376)
Other comprehensive income (loss) before reclassifications	4,960
Reclassification adjustments	-2,340
Ending Balance	2,244
Foreign Currency Translation [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning Balance	-5,829
Other comprehensive income (loss) before reclassifications	4,173
Ending Balance	-1,656
Marketable Securities [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning Balance	5,708
Other comprehensive income (loss) before reclassifications	-753
Reclassification adjustments	-5,004
Ending Balance	-49
Derivative Instruments [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning Balance	-20,855
Other comprehensive income (loss) before reclassifications	1,142
Reclassification adjustments	2,026
Ending Balance	-17,687
Defined Benefit Plans [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning Balance	-5,044
Reclassification adjustments	385
Ending Balance	-4,659
Income Taxes [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning Balance	25,644
Other comprehensive income (loss) before reclassifications	398
Reclassification adjustments	253
Ending Balance	$26,295

Comprehensive_Income_Summary_o1

Comprehensive Income - Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'
Amortization of prior service costs	$20	$83	$40	$172
Marketable securities, Other expense (income), net	3,056	536	-1,788	-1,846
Amortization of actuarial losses	173	166	345	344
Income tax expense/benefit	-32,400	-8,830	-69,789	-40,948
Foreign exchange forward contracts, Service revenues	-1,341,030	-1,295,680	-2,648,876	-2,524,521
Marketable Securities [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'
Marketable securities, Other expense (income), net	'	'	-5,004	'
Total before income taxes	'	'	-5,004	'
Income tax expense/benefit	'	'	-1,927	'
Total net of income taxes	'	'	-3,077	'
Defined Benefit Plans [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'
Amortization of prior service costs	20	83	40	172
Amortization of actuarial losses	173	166	345	344
Total before income taxes	193	249	385	516
Income tax expense/benefit	72	94	144	195
Total net of income taxes	121	155	241	321
Derivative [Member] | Derivative Instruments [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'
Total before income taxes	857	3,592	2,026	7,506
Income tax expense/benefit	736	1,320	1,530	2,688
Total net of income taxes	121	2,272	496	4,818
Interest Rate Swaps [Member] | Derivative Instruments [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'
Interest rate swaps, Interest expense	3,115	3,179	6,195	6,185
Foreign Exchange Forward Contracts [Member] | Derivative Instruments [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'
Foreign exchange forward contracts, Service revenues	($2,258)	$413	($4,169)	$1,321

Segments_Additional_Informatio

Segments - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2014
		Segment
Segment Reporting [Abstract]	'	'
Number of reportable segments	'	2
Management agreement termination fee	$25	'
Agreement modification fee	$1.50	'

Segments_Operations_by_Reporta

Segments - Operations by Reportable Segments (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Service revenues	$1,035,476	$944,238	$2,040,764	$1,871,673
Costs of revenue, service costs	674,514	617,666	1,318,236	1,228,775
Selling, general and administrative	219,014	228,838	438,256	428,140
Income from operations	141,000	94,897	282,316	210,062
Restructuring costs	-948	-2,837	-1,956	-4,696
Operating Segments [Member] | Product Development [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Service revenues	781,187	724,170	1,552,015	1,430,477
Costs of revenue, service costs	465,278	441,895	915,761	870,902
Selling, general and administrative	157,552	146,182	317,237	290,807
Income from operations	158,357	136,093	319,017	268,768
Operating Segments [Member] | Integrated Healthcare Services [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Service revenues	254,289	220,068	488,749	441,196
Costs of revenue, service costs	209,236	175,771	402,475	357,873
Selling, general and administrative	33,346	31,790	65,622	64,571
Income from operations	11,707	12,507	20,652	18,752
Corporate, Non-Segment [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Selling, general and administrative	28,116	50,866	55,397	72,762
Income from operations	-28,116	-50,866	-55,397	-72,762
Segment Reconciling Items [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Restructuring costs	($948)	($2,837)	($1,956)	($4,696)

Segments_Depreciation_and_Amor

Segments - Depreciation and Amortization Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization expense	$29,845	$24,986	$58,933	$49,626
Operating Segments [Member] | Product Development [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization expense	23,791	18,601	46,761	37,048
Operating Segments [Member] | Integrated Healthcare Services [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization expense	4,854	5,267	9,745	10,620
Corporate, Non-Segment [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization expense	$1,200	$1,118	$2,427	$1,958

Earnings_Per_Share_Summary_of_

Earnings Per Share - Summary of Weighted-Average Outstanding Share-Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Weighted average shares subject to anti-dilutive share-based awards	1,598	1,217	1,182	1,424

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event [Member], Encore Health Resources [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Jul. 01, 2014
Subsequent Event [Member] | Encore Health Resources [Member]	'
Subsequent Event [Line Items]	'
Business acquisition through merger	$93.60